申请人:STERLING DRUG INC.
公开号:EP0191298A2
公开(公告)日:1986-08-20
Naphthyridin-2(1 H)-ones, having the formula I
or salts thereof, where Z is hydrogen or cyano, and Q is 2 (or 3)-furanyl, 2(or 3)-thienyl, 4(or 3)-pyridinyl or 4(or 3)-pyridinyl having one or two methyl substituents, are useful as cardiotonic agents and corresponding compounds where Z is carboxy are useful as intermediates. Also shown as intermediates are 5-(Q-CO)-6-[2(di-lower-alkylamino)-ethenyl]-2(1H)-pyridinones (II) or salts thereof, where Q is defined as above. A process for preparing the compounds (I) comprises reacting a compound (II) with formamidine, ammonia or a salt thereof.
萘啶-2(1H)-酮,具有式 I
或其盐,其中 Z 为氢或氰基,Q 为 2(或 3)-呋喃基、2(或 3)-噻吩基、4(或 3)-吡啶基或具有一个或两个甲基取代基的 4(或 3)-吡啶基,可用作强心剂,Z 为羧基的相应化合物可用作中间体。作为中间体的还有 5-(Q-CO)-6-[2(二低烷基氨基)-乙烯基]-2(1H)-吡啶酮 (II) 或其盐,其中 Q 的定义同上。制备化合物(I)的工艺包括使化合物(II)与甲脒,氨或其盐反应。